Clinical Trials Browser

famitinib × 1 year × Clear all

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06649331 2026-04-08

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Phase 2 Not yet recruiting

Melanoma

NCT07382713 2026-02-03

Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT07355010 2026-01-21

A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT07266350 2025-12-05

A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer

Not yet recruiting

Cervical Cancer Metastatic

NCT07143292 2025-11-18

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

Phase 2 Not yet recruiting

Cervical Cancer Metastatic

NCT04619433 2025-09-23

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Phase 3 Terminated

Non-squamous Non-small-cell Lung Cancer

NCT05208177 2025-08-22

A Study of SHR-1802 in Patients With Advanced Solid Tumor

Phase 2 Terminated

Other solid neoplasm

Advanced Solid Tumor

NCT05582499 2025-08-22

FASCINATE-N

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

Uterine Cervical Neoplasms, Recurrence

NCT06913777 2025-06-06

Neoadjuvant SNF Precision Therapy Phase III

Phase 3 Recruiting

Neoadjuvant Therapy